Wedbush has issued an earnings estimate for NovoCure Limited (NASDAQ:NVCR) for fiscal year 2022.
Wedbush decreased its forecast for the earnings per share (EPS) that NovoCure Limited (NVCR: NASDAQ) will generate during the fiscal year 2022 in a research …